Bringing the Oncology Community Together

5 Questions for Martin Steffen, MD, PhD

Jane de Lartigue, PhD
Published Online: Thursday, December 15, 2011
Dr. Martin Steffen

Martin Steffen, MD, PhD

Martin Steffen, MD, PhD, is a principal investigator at Boston University School of Medicine in the Department of Pathology and Laboratory Medicine, and the Department of Biomedical Engineering. Partnering with Simon Kasif, PhD, also of BU, he developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

1

What is the role of protein phosphorylation in a normal cell?

The phosphorylation of a protein is a covalent chemical modification that can regulate the activity of the protein. In basic terms, it can be thought of as an “on/off” switch for the particular protein that is phosphorylated.

2

How is dysregulated protein phosphorylation implicated in cancer?

In cancers, it is frequently found that proteins are aberrantly phosphorylated, often due to a mutation somewhere in the cancer genome. This can have the effect of turning a protein “on” when in normal tissue the protein should be in an “off” state. This is especially true of signaling proteins that drive cellular proliferation.

3

How has our understanding of protein phosphorylation been exploited in cancer research and drug development?

One of the most exciting new classes of drugs is the tyrosine kinase inhibitors (TKIs). These drugs target protein phosphorylation events, blocking them in an attempt to prevent the tumor from proliferating. The results can be dramatic; one of the first TKIs, Gleevec (imatinib), showed great initial efficacy for gastrointestinal stromal tumors.

4

How can we use protein phosphorylation status as a biomarker or prognostic indicator?

We believe that the patterns of phosphorylation in a cell will reveal the pathways that are activated in those tumors, and therefore suggest which drugs might be efficacious for those tumors. Many others are attempting to do the same by looking at DNA mutations in the cancers. Both avenues are very promising.

5

What are the future challenges to our understanding of protein phosphorylation?

One goal would be a comprehensive catalog of the phosphorylation status of all proteins in tumors. A second goal would be knowledge of the tumor’s “weak points,” basically knowing which phosphorylated proteins could be targeted to maximally destroy the tumor cells, while preserving normal tissue.

Related Articles
Adjuvant EGFR Inhibition in Patients With NSCLC
In this segment, panelists discuss the investigation of EGFR inhibitors as adjuvant treatments for patients with resected non-small cell lung cancer.
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.